GeneDx Holdings (WGS) Gross Profit (2020 - 2026)

GeneDx Holdings (WGS) has reported Gross Profit for 7 consecutive years, with $78.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Gross Profit rose 10.35% year-over-year to $78.2 million in Q2 2026; TTM through Jun 2026 was $315.2 million, a 29.51% increase from a year earlier, with the FY2025 full-year figure at $298.2 million, up 53.38% from the prior year.
• Gross Profit was $78.2 million for Q2 2026 at GeneDx Holdings, up from $68.2 million in the prior quarter.
• Over five years, Gross Profit peaked at $84.5 million in Q3 2025 and troughed at -$29.6 million in Q2 2022.
• A 5-year average of $39.0 million and a median of $40.2 million in 2024 frame the typical range for Gross Profit.
• Across the five-year window, Gross Profit tumbled 2442.78% in 2022 and surged 288.37% in 2023, its largest moves.
• Over 5 years, Gross Profit stood at -$16.3 million in 2022, then surged by 288.37% to $30.8 million in 2023, then soared by 115.27% to $66.2 million in 2024, then climbed by 27.28% to $84.3 million in 2025, then fell by 7.16% to $78.2 million in 2026.
• The last three Gross Profit figures came in at $78.2 million (Q2 2026), $68.2 million (Q1 2026), and $84.3 million (Q4 2025), per Business Quant data.